{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:14:40Z","timestamp":1793646880952,"version":"4.5.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Summary\n<\/jats:title>\n                <jats:p>Trends in bone mineral density monitoring, and drug treatment for osteoporosis, in Australia were examined. Rates of DEXA scanning have increased in response to changes to government policy affecting reimbursement. The drug denosumab is being utilised at an increasing rate, while bisphosphonate use has declined. Osteoporosis prevalence remained stable over the same timeframe, while rate of hip fractures declined, suggesting that introduction of osteoporosis screening was associated with a reduction in adverse osteoporosis outcomes, but may also have been associated with overutilisation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Radiology interventions to diagnose and medications to manage osteoporosis in Australia are reimbursed under the Medicare benefits schedule (MBS) and Pharmaceutical Benefits Scheme (PBS). Monitoring of these databases enables changes in utilisation of these practices to be monitored over time. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study examined rates of utilisation for bone mineral density (BMD) measurement and osteoporosis pharmacotherapy subsidised under the MBS. Rates of osteoporosis and hip fracture were estimated using data reported by the Australian Bureau of Statistics (ABS) and Australian Institute for Health and Welfare (AIHW). <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Rates of BMD measurement increased since the technology was first reimbursed, with changes to policy regarding reimbursement for screening for individuals over 70 leading to an increase in BMD measurement after 2007. Prescribing rates also increased over time, initially with the introduction of oral bisphosphonates and subsequently for denosumab, which has subsequently become the most commonly prescribed agent for osteoporosis management in Australia, while bisphosphonate use has declined. Osteoporosis prevalence in Australia has remained relatively static at 3\u20134% of the population since 2001 to 2017, while rates of minimal trauma hip fracture hospitalisations have declined from 195 per 100,000 to 174 per 100,000 in the same timeframe. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Available data indicates that osteoporosis screening rates changed over time from 2001 to 2018 and that changes to government policy had a significant effect on the rates at which screening was performed. Over the same timeframe, there was a sustained reduction in hip fracture hospitalisation rates, with no change to reported osteoporosis prevalence. This suggests that policy changes permitting unlimited access to BMD measurement were associated with a reduction in osteoporotic fractures, but may also have been associated with overutilisation. Prospective studies to assess the efficacy of specific policies to ensure screening is performed in accordance with best-practice guidelines may be desirable. \n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11657-022-01139-0","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T22:02:35Z","timestamp":1658268155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Trends in osteoporosis diagnosis and management in Australia"],"prefix":"10.1007","volume":"17","author":[{"given":"Leon","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"1139_CR1","unstructured":"Osteoporosis, Data [Internet]. Australian Institute of Health and Welfare. [cited 2022 Feb 25]. Available from: https:\/\/www.aihw.gov.au\/reports\/chronic-musculoskeletal-conditions\/osteoporosis\/data"},{"key":"1139_CR2","unstructured":"Walker BR, Colledge NR, Ralston S, Penman ID, Britton R, editors. Davidson\u2019s principles and practice of medicine. 22nd edition. Edinburgh\u00a0; New York: Churchill Livingstone\/Elsevier; 2014. 1372 p."},{"key":"1139_CR3","doi-asserted-by":"crossref","unstructured":"Milat F, Ebeling PR. Osteoporosis treatment: a missed opportunity. Med J Aust [Internet]. 2016 Aug 15 [cited 2022 Mar 1];205(4). Available from: https:\/\/www.mja.com.au\/journal\/2016\/205\/4\/osteoporosis-treatment-missed-opportunity","DOI":"10.5694\/mja16.00568"},{"issue":"may26 12","key":"1139_CR4","doi-asserted-by":"publisher","first-page":"h2088","DOI":"10.1136\/bmj.h2088","volume":"350","author":"TL Jarvinen","year":"2015","unstructured":"Jarvinen TL, Michaelsson K, Jokihaara J, Collins GS, Perry TL, Mintzes B et al (2015) Overdiagnosis of bone fragility in the quest to prevent hip fracture. BMJ 350(may26 12):h2088\u2013h2088","journal-title":"BMJ"},{"issue":"7636","key":"1139_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1136\/bmj.39435.656250.AD","volume":"336","author":"P Alonso-Coello","year":"2008","unstructured":"Alonso-Coello P, Garcia-Franco AL, Guyatt G, Moynihan R (2008) Drugs for pre-osteoporosis: prevention or disease mongering? BMJ 336(7636):126\u2013129","journal-title":"BMJ"},{"issue":"24","key":"1139_CR6","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama.2018.7498","volume":"319","author":"US Preventive Services Task Force","year":"2018","unstructured":"US Preventive Services Task Force (2018) Screening for osteoporosis to prevent fractures: US Preventive Services Task Force Recommendation Statement. JAMA 319(24):2521\u20132531","journal-title":"JAMA"},{"key":"1139_CR7","unstructured":"Health AGD of. Pharmaceutical Benefits Scheme (PBS) | Home [Internet]. Australian Government Department of Health; [cited 2016 Feb 23]. Available from: http:\/\/www.pbs.gov.au\/pbs\/home"},{"key":"1139_CR8","unstructured":"Health AGD of. Changes to Medicare Benefits Schedule (MBS) items for bone densitometry [Internet]. Australian Government Department of Health; [cited 2022 Feb 22]. Available from: http:\/\/www.mbsonline.gov.au\/internet\/mbsonline\/publishing.nsf\/Content\/Factsheet-MBSBoneDensitometryItems"},{"key":"1139_CR9","doi-asserted-by":"publisher","first-page":"115390","DOI":"10.1016\/j.bone.2020.115390","volume":"137","author":"IR Reid","year":"2020","unstructured":"Reid IR, Green JR, Lyles KW, Reid DM, Trechsel U, Hosking DJ et al (2020) Zoledronate Bone 137:115390","journal-title":"Zoledronate Bone"},{"issue":"12","key":"1139_CR10","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/ijcp.12022","volume":"66","author":"DA Hanley","year":"2012","unstructured":"Hanley DA, Adachi JD, Bell A, Brown V (2012) Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 66(12):1139\u20131146","journal-title":"Int J Clin Pract"},{"key":"1139_CR11","unstructured":"Health AGD of. Pharmaceutical Benefits Scheme (PBS) | [Internet]. Australian Government Department of Health; [cited 2022 Feb 25]. Available from: https:\/\/www.pbs.gov.au\/medicine\/item\/9411H"},{"key":"1139_CR12","unstructured":"ABS Statistics [Internet]. [cited 2015 Dec 18]. Available from: http:\/\/stat.abs.gov.au\/"},{"key":"1139_CR13","unstructured":"National Health Survey: First results, 2017\u201318 financial year | Australian Bureau of Statistics [Internet]. 2018 [cited 2022 Feb 25]. Available from: https:\/\/www.abs.gov.au\/statistics\/health\/health-conditions-and-risks\/national-health-survey-first-results\/latest-release"},{"key":"1139_CR14","unstructured":"Australian Institute of Health and Welfare. Hip fracture incidence and hospitalisations in Australia 2015\u201316. [Internet]. 2018 [cited 2022 Feb 28]. Available from: https:\/\/www.aihw.gov.au\/reports\/injury\/hip-fracture-incidence-in-australia-2015-16\/contents\/table-of-contents"},{"issue":"9","key":"1139_CR15","first-page":"555","volume":"61","author":"KW Craig","year":"2012","unstructured":"Craig KW, Stevermer JJ (2012) DEXA screening\u2014are we doing too much? J Fam Pract 61(9):555\u2013556","journal-title":"J Fam Pract"},{"key":"1139_CR16","doi-asserted-by":"crossref","unstructured":"Cromer SJ, D\u2019Silva KM, Yu EW, Landon J, Desai RJ, Kim SC 2021 Secular trends in the pharmacologic treatment of osteoporosis and malignancy-related bone disease from 2009 to 2020. J Gen Intern Med. 2021 Jun 7;","DOI":"10.1007\/s11606-021-06938-8"},{"issue":"12","key":"1139_CR17","doi-asserted-by":"crossref","first-page":"204201882110100","DOI":"10.1177\/20420188211010052","volume":"1","author":"JA Noble","year":"2021","unstructured":"Noble JA, McKenna MJ, Crowley RK (2021) Should denosumab treatment for osteoporosis be continued indefinitely? Ther Adv Endocrinol Metab 1(12):20420188211010052","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"3","key":"1139_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/20009666.2019.1618660","volume":"9","author":"R Dhital","year":"2019","unstructured":"Dhital R, Lynn T, Tachamo N, Poudel DR (2019) The trend of osteoporosis and osteoporotic fragility fractures in inpatients: results from a national database. J Community Hosp Intern Med Perspect 9(3):211\u2013214","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"12","key":"1139_CR19","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1377\/hlthaff.2011.0233","volume":"30","author":"AB King","year":"2011","unstructured":"King AB, Fiorentino DM (2011) Medicare payment cuts for osteoporosis testing reduced use despite tests\u2019 benefit in reducing fractures. Health Aff Proj Hope 30(12):2362\u20132370","journal-title":"Health Aff Proj Hope"},{"issue":"4","key":"1139_CR20","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jocd.2010.08.001","volume":"13","author":"BL Hayes","year":"2010","unstructured":"Hayes BL, Curtis JR, Laster A, Saag K, Tanner SB, Liu C et al (2010) Osteoporosis care in the United States after declines in reimbursements for DXA. J Clin Densitom Off J Int Soc Clin Densitom 13(4):352\u2013360","journal-title":"J Clin Densitom Off J Int Soc Clin Densitom"},{"key":"1139_CR21","unstructured":"Osteoporosis - UK National Screening Committee (UK NSC) - GOV.UK [Internet]. [cited 2022 May 17]. Available from: https:\/\/view-health-screening-recommendations.service.gov.uk\/osteoporosis\/"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-022-01139-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-022-01139-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-022-01139-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T14:26:53Z","timestamp":1678976813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-022-01139-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1139"],"URL":"https:\/\/doi.org\/10.1007\/s11657-022-01139-0","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"assertion":[{"value":"5 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"97"}}